Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis

site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
vertical-expand: a:0:{}
caf_enhance: 0
Drug Category: Array
Conference Category: Array
Lead Author: Alvarez ER. et al.
Published Date: 23/10/2024
Download Link: /wp-content/uploads/2024/10/NEDA-ULTIMATE-I-and-II-Oct-2024.pdf
Download Text:
Popup Confirmation?:
astra-migrate-meta-layouts: set
Scroll to Top